LABELS · 6d914dea-626d-4402-8fce-29760fd0e34f

DOCIVYX

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-07-15
Captured: 2026-09-09T23:37:51.659493+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with DOCIVYX is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive DOCIVYX as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions (5.1) ] . Avoid the use of DOCIVYX in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of DOCIVYX [see Warnings and Precautions (5.2) ] . Do not administer DOCIVYX to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection. [see Warnings and Precautions (5.3) ] . Do not administer DOCIVYX to patients who have a history of severe hypersensitivity reactions to DOCIVYX [see Contraindications (4) ] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the DOCIVYX infusion and administration of appropriate therapy [see Warnings and Precautions (5.5) ] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.6) ] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving DOCIVYX at 100 mg/m 2 ( 5.1 ) Avoid use of DOCIVYX if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) Do not administer DOCIVYX to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of DOCIVYX and administration of appropriate therapy ( 5.5 ) Contraindicated if history of severe hypersensitivity reactions to DOCIVYX ( 4 ) Severe fluid retention may occur despite dexamethasone ( 5.6 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE DOCIVYX is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. DOCIVYX in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC. 1.4 Gastric Adenocarcinoma DOCIVYX in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer DOCIVYX in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Full extracted label fields

application numbers

NDA215813

boxed warning exact

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with DOCIVYX is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive DOCIVYX as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions (5.1) ] . Avoid the use of DOCIVYX in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of DOCIVYX [see Warnings and Precautions (5.2) ] . Do not administer DOCIVYX to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection. [see Warnings and Precautions (5.3) ] . Do not administer DOCIVYX to patients who have a history of severe hypersensitivity reactions to DOCIVYX [see Contraindications (4) ] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the DOCIVYX infusion and administration of appropriate therapy [see Warnings and Precautions (5.5) ] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.6) ] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving DOCIVYX at 100 mg/m 2 ( 5.1 ) Avoid use of DOCIVYX if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) Do not administer DOCIVYX to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of DOCIVYX and administration of appropriate therapy ( 5.5 ) Contraindicated if history of severe hypersensitivity reactions to DOCIVYX ( 4 ) Severe fluid retention may occur despite dexamethasone ( 5.6 )

brand names

DOCIVYX

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4763744e-360e-4d37-be05-cce4114548cd

generic names

DOCETAXEL

6d914dea-626d-4402-8fce-29760fd0e34f

indications and usage exact

1 INDICATIONS AND USAGE DOCIVYX is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. DOCIVYX in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC. 1.4 Gastric Adenocarcinoma DOCIVYX in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer DOCIVYX in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

indications and usage tables exact

is original packager

true

manufacturer names

Avyxa Pharma, LLC

matched search terms

cancer
carcinoma

package ndcs

83831-101-02
83831-102-08
83831-103-16

product ndcs

83831-101
83831-102
83831-103

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1860619
2679779
2679784
2679786
2679787
2679788

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00400.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1059
end exclusive: true
exact text: 1 INDICATIONS AND USAGE DOCIVYX is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. DOCIVYX in combination with doxorubicin and
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 0

current approval status

not_reconciled

duplicate text group

dup-f681a40e90a514e20da1

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-a9beda2fa74103b76493

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 68
end exclusive: true
exact text: is a microtubule inhibitor indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 32

qualifier mentions

context exact
: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant trea
kind
biomarker
polarity
not_inferred
span
end
172
end exclusive
true
exact text
metastatic BC after chemotherapy failure
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
132
context exact
l Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced
kind
biomarker
polarity
not_inferred
span
end
391
end exclusive
true
exact text
metastatic NSCLC after platinum therapy fai
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
348
context exact
e; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration- Resistant Prostate Cancer (CRPC) : with pre
kind
biomarker
polarity
not_inferred
span
end
484
end exclusive
true
exact text
metastatic untreated NSCLC ( 1
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
454
context exact
tion- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorou
kind
biomarker
polarity
not_inferred
span
end
574
end exclusive
true
exact text
metastatic CRPC ( 1
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
555
context exact
ibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adju
kind
stage_or_setting
polarity
not_inferred
span
end
163
end exclusive
true
exact text
locally advanced or metastatic BC after chemotherap
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
112
context exact
erapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agen
kind
stage_or_setting
polarity
not_inferred
span
end
262
end exclusive
true
exact text
adjuvant treatment of operable node-positiv
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
219
context exact
1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, local
kind
stage_or_setting
polarity
not_inferred
span
end
379
end exclusive
true
exact text
locally advanced or metastatic NSCLC after platinum
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
328
context exact
SCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Cas
kind
stage_or_setting
polarity
not_inferred
span
end
432
end exclusive
true
exact text
unresectable
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
420
context exact
tinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration- Resistant Prostate Cancer (CRPC) : with pre
kind
stage_or_setting
polarity
not_inferred
span
end
484
end exclusive
true
exact text
locally advanced or metastatic untreated NSCLC ( 1
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
434
context exact
tion- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorou
kind
stage_or_setting
polarity
not_inferred
span
end
574
end exclusive
true
exact text
metastatic CRPC ( 1
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
555
context exact
cinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous C
kind
stage_or_setting
polarity
not_inferred
span
end
666
end exclusive
true
exact text
advanced GC
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
655
context exact
with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
855
end exclusive
true
exact text
locally advanced SCCHN ( 1
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
829

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 859
end exclusive: true
exact text: 1 INDICATIONS AND USAGE DOCIVYX is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1215
end exclusive: true
exact text: ced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer DOCIVYX as a
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 660

current approval status

not_reconciled

duplicate text group

dup-135d6f53200686baf080

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-c303380b222d3a618e38

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 898
end exclusive: true
exact text: is indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 886

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
997
end exclusive
true
exact text
metastatic breast cancer after failure of p
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
954
context exact
cer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
985
end exclusive
true
exact text
locally advanced or metastatic breast cancer after
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
934

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 1015
end exclusive: true
exact text: 1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 860

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1371
end exclusive: true
exact text: treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-base
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 816

current approval status

not_reconciled

duplicate text group

dup-364812db71679695de3f

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-a9710886a061a21560a8

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 1089
end exclusive: true
exact text: is indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1077

qualifier mentions

context exact
with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1141
end exclusive
true
exact text
adjuvant treatment of patients with operabl
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1098
context exact
DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
regimen
polarity
not_inferred
span
end
1170
end exclusive
true
exact text
in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1024

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 1171
end exclusive: true
exact text: DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1016

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1586
end exclusive: true
exact text: cancer after failure of prior chemotherapy. DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. DOCIVYX in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemothe
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 972

current approval status

not_reconciled

duplicate text group

dup-0e1dd8193758ac1e320a

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-ebc1438032bc7020cd3f

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 1241
end exclusive: true
exact text: is indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1229

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1340
end exclusive
true
exact text
metastatic non-small cell lung cancer after
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1297
context exact
ingle agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1328
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1277
context exact
1.2 Non-small Cell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
regimen
polarity
not_inferred
span
end
1385
end exclusive
true
exact text
as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1211

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 1386
end exclusive: true
exact text: 1.2 Non-small Cell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1172

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1810
end exclusive: true
exact text: ell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. DOCIVYX in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC. 1.4 Gastric Adenocarcinoma DOCIVYX in combination with cisplatin and fluoro
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1187

current approval status

not_reconciled

duplicate text group

dup-329b2cc5ef4b48c413b2

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-4df42715e805dbdbab50

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 1437
end exclusive: true
exact text: is indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1425

qualifier mentions

context exact
reatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
biomarker
polarity
not_inferred
span
end
1550
end exclusive
true
exact text
metastatic non-small cell lung cancer who h
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1507
context exact
h cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer
kind
stage_or_setting
polarity
not_inferred
span
end
1485
end exclusive
true
exact text
unresectable
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1473
context exact
indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for thi
kind
stage_or_setting
polarity
not_inferred
span
end
1538
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1487
context exact
DOCIVYX in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
regimen
polarity
not_inferred
span
end
1574
end exclusive
true
exact text
in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1395

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 1610
end exclusive: true
exact text: DOCIVYX in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1387

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1934
end exclusive: true
exact text: ith cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC. 1.4 Gastric Adenocarcinoma DOCIVYX in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gast
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1411

current approval status

not_reconciled

duplicate text group

dup-f4f3fadfda1aa882a6f6

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-4429e23fcc0d2200c912

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 1682
end exclusive: true
exact text: is indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1670

qualifier mentions

context exact
prednisone is indicated for the treatment of patients with metastatic CRPC.
kind
biomarker
polarity
not_inferred
span
end
1733
end exclusive
true
exact text
metastatic CRPC
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1718
context exact
prednisone is indicated for the treatment of patients with metastatic CRPC.
kind
stage_or_setting
polarity
not_inferred
span
end
1733
end exclusive
true
exact text
metastatic CRPC
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1718
context exact
1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC.
kind
regimen
polarity
not_inferred
span
end
1733
end exclusive
true
exact text
in combination with prednisone is indicated for the treatment of patients with metastatic CRPC
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1639

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 1734
end exclusive: true
exact text: 1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC.
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1611

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2219
end exclusive: true
exact text: ng cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC. 1.4 Gastric Adenocarcinoma DOCIVYX in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer DOCIVYX in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1535

current approval status

not_reconciled

duplicate text group

dup-64e9d71c2724336530bb

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-354be7c58659cb308626

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 1829
end exclusive: true
exact text: is indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1817

qualifier mentions

context exact
luorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction,
kind
stage_or_setting
polarity
not_inferred
span
end
1896
end exclusive
true
exact text
advanced gastric adenocarcinoma
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1865
context exact
geal junction, who have not received prior chemotherapy for advanced disease.
kind
stage_or_setting
polarity
not_inferred
span
end
2018
end exclusive
true
exact text
advanced disease
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
2002
context exact
1.4 Gastric Adenocarcinoma DOCIVYX in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advance
kind
regimen
polarity
not_inferred
span
end
1949
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal ju
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
1770

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 2019
end exclusive: true
exact text: 1.4 Gastric Adenocarcinoma DOCIVYX in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1735

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 8 · positive indication candidate

application numbers

NDA215813

brand names

DOCIVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2228
end exclusive: true
exact text: indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer DOCIVYX in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 1820

current approval status

not_reconciled

duplicate text group

dup-3e4e3dd15c72f6307b59

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-f752a4ff17d03bd68877

label id

6d914dea-626d-4402-8fce-29760fd0e34f

positive predicate support span

end: 2112
end exclusive: true
exact text: is indicated
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 2100

qualifier mentions

context exact
l is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
stage_or_setting
polarity
not_inferred
span
end
2209
end exclusive
true
exact text
locally advanced squamous cell carcinoma of the hea
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
2158
context exact
1.5 Head and Neck Cancer DOCIVYX in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
regimen
polarity
not_inferred
span
end
2227
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
2053

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
309
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
6d914dea-626d-4402-8fce-29760fd0e34f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start
275

source span

end: 2228
end exclusive: true
exact text: 1.5 Head and Neck Cancer DOCIVYX in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 6d914dea-626d-4402-8fce-29760fd0e34f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d51ac1dc9765bcb8cde23ad00cb9c5f0a6816523aedd5433c890c7de99e32054
start: 2020

source url

https://api.fda.gov/drug/label.json?search=id%3A%226d914dea-626d-4402-8fce-29760fd0e34f%22

spl effective date

2025-07-15

spl set id

4763744e-360e-4d37-be05-cce4114548cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice